Peritubular Capillary Rarefaction: An Underappreciated Regulator of CKD Progression

Autor: Yujiro Kida
Rok vydání: 2020
Předmět:
0301 basic medicine
Senescence
endocrine system diseases
Angiogenesis
030232 urology & nephrology
Regulator
Neovascularization
Physiologic
Renal function
Rarefaction
Apoptosis
Cell Count
pericyte detachment
Review
peritubular capillary
urologic and male genital diseases
Catalysis
Inorganic Chemistry
Diabetic nephropathy
03 medical and health sciences
0302 clinical medicine
Animals
Humans
Medicine
Renal Insufficiency
Chronic
Physical and Theoretical Chemistry
Molecular Biology
Cellular Senescence
Spectroscopy
business.industry
Organic Chemistry
Endothelial Cells
General Medicine
medicine.disease
Capillaries
Computer Science Applications
Kidney Tubules
030104 developmental biology
Disease Progression
endothelial cell
Cancer research
Kidney Failure
Chronic
Pericytes
business
chronic kidney disease
Nephrosclerosis
Kidney disease
Zdroj: International Journal of Molecular Sciences
ISSN: 1422-0067
DOI: 10.3390/ijms21218255
Popis: Peritubular capillary (PTC) rarefaction is commonly detected in chronic kidney disease (CKD) such as hypertensive nephrosclerosis and diabetic nephropathy. Moreover, PTC rarefaction prominently correlates with impaired kidney function and predicts the future development of end-stage renal disease in patients with CKD. However, it is still underappreciated that PTC rarefaction is a pivotal regulator of CKD progression, primarily because the molecular mechanisms of PTC rarefaction have not been well-elucidated. In addition to the established mechanisms (reduced proangiogenic factors and increased anti-angiogenic factors), recent studies discovered significant contribution of the following elements to PTC loss: (1) prompt susceptibility of PTC to injury, (2) impaired proliferation of PTC, (3) apoptosis/senescence of PTC, and (4) pericyte detachment from PTC. Mainly based on the recent and novel findings in basic research and clinical study, this review describes the roles of the above-mentioned elements in PTC loss and focuses on the major factors regulating PTC angiogenesis, the assessment of PTC rarefaction and its surrogate markers, and an overview of the possible therapeutic agents to mitigate PTC rarefaction during CKD progression. PTC rarefaction is not only a prominent histological characteristic of CKD but also a central driving force of CKD progression.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje